Judge Dismisses Complaint Against McNeil Related To Recalled OTCs
This article was originally published in The Tan Sheet
A federal judge in Philadelphia tossed out a complaint alleging McNeil Consumer Healthcare overcharged for OTC products that the firm recalled due to quality control issues at its Fort Washington, Pa., facility beginning in 2010.
You may also be interested in...
Plan B One-Step gets generic competition; legislation to restrict DXM introduced again; J&J agrees to reforms in settlement; China recants on MJN formula concerns; Buster line drives Hi-Tech Pharmacal OTC growth; Sabinsa awarded profits from infringed ForsLean trademark; more news In Brief.
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
Johnson & Johnson faces lawsuits filed by consumers in federal court, alleging fraud and other problems leading up to and following the firm's extensive recall of pediatric OTC drug products